LFMD LifeMD (LFMD) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-offices & clinics of doctors of medicine · CIK 0000948320
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
71
13F, latest reported quarter
LifeMD insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for LifeMD, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 14, 2025.
- The trade is 7.3% of the 205,000 shares held after it.
- No other insider sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Marketing Officer FRIEDEMAN JESSICA sold about $54.1K of LFMD on Dec 9, 2025; 71 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 14, 2023.
- The trade is 12.4% of the 605,000 shares held after it.
- No other insider sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Acquisition Officer Alvarez Nicholas P sold about $444.0K of LFMD on Sep 10, 2025; 71 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Jun 2, 2025.
- +79.5% median (+79.5% mean) 90-day return after 2 previous buys.
- The trade is 1.0% of the 2,475,721 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Schreiber Justin sold about $249.8K of LFMD on Jul 1, 2025; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Jun 2, 2025.
- +79.5% median (+79.5% mean) 90-day return after 2 previous buys.
- The trade is 1.0% of the 2,500,721 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO Schreiber Justin sold about $334.5K of LFMD on Jul 1, 2025; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (6 buys, 1 sale), the last on Jun 16, 2025.
- -22.4% median (-22.4% mean) 90-day return after 2 previous buys.
- The trade is 14.7% of the 339,554 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Benathen Marc David sold about $700.5K of LFMD on Jun 17, 2025; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.60 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
71 funds bought in last quarter
below 72% of Healthcare Services
Revenue
+25.3% year over year
more than 77% of Healthcare Services
Margin
7.4% net margin
more than 80% of Healthcare Services
Buybacks
$270.0K repurchased, FY to 2025-12-31
below 94% of Healthcare Services
Short interest
18.6% of the float short (float per yahoo 2026-10-27) · 11.0 days to cover · settled 2026-10-15
more than 92% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LFMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-66.6%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LFMD: institutional holders (13F)
13F holdings, latest reported quarter
3,034,535 sh
$12.5M
2,747,655 sh
$11.3M
1,734,756 sh
$7.2M
1,318,784 sh
$5.4M
1,079,525 sh
$4.5M
Congress trades in LFMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
LFMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LFMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Federated Hermes MDT Small Cap Growth Fund
$2.8M position · as of 2026-07-31
0.3%
Federated Hermes MDT Small Cap Core Fund
$5.5M position · as of 2026-07-31
0.2%
KraneShares Man Buyout Beta Index ETF
$40.0K position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$291.2K position · as of 2026-06-30
0.2%
Royce Quant Small-Cap Quality Value ETF
$36.6K position · as of 2026-06-30
0.1%
Royce Small-Cap Opportunity Fund
$1.2M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Schreiber
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$777.1K
$777.1K
$1.6M
-48%
n/a
2024
$1.1M
$1.1M
$1.1M
-37%
n/a
2023
$888.8K
$948.3K
$2.1M
+6%
n/a
2022
$255.0K
$255.0K
$1.1M
-70%
n/a
2021
$180.0K
$180.0K
$5.9M
-41%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 71 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LFMD financials
Revenue growth
+25.3%
XBRL, annual
Net margin
7.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM LFMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $152.5M |
| FY Dec 2022 | $119.0M |
| FY Dec 2021 | $92.9M |
| Jun 2026 | $47.3M |
| Mar 2026 | $50.2M |
| Dec 2025 | $7.1M |
| Sep 2025 | $60.2M |
| Jun 2025 | $62.7M |
| Mar 2025 | $65.7M |
| Dec 2024 | $63.1M |
| Sep 2024 | $53.4M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM LFMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +11.7% |
| FY Dec 2022 | -38.3% |
| FY Dec 2021 | -65.6% |
| Jun 2026 | -15.0% |
| Mar 2026 | -17.7% |
| Dec 2025 | -79.6% |
| Sep 2025 | -6.3% |
| Jun 2025 | -2.6% |
| Mar 2025 | -0.3% |
| Dec 2024 | +64.9% |
| Sep 2024 | -8.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$11.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LFMD
| FY Dec 2025 | $6.4M |
| FY Dec 2024 | $16.0M |
| FY Dec 2023 | $8.6M |
| FY Dec 2022 | -$23.3M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$7.0M |
| Mar 2026 | $339.4K |
| Dec 2025 | -$3.4M |
| Sep 2025 | -$968.1K |
| Jun 2025 | $7.9M |
| Mar 2025 | $3.0M |
| Dec 2024 | $875.4K |
| Sep 2024 | $6.3M |
At each fiscal year end
Single quarter
Debt to equity
2.00x
long-term debt only, 2025-06-30 (12 months older than the period end); equity 2026-06-30
Debt to equity LFMD
| FY Dec 2025 | 0.69x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 5.11x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.48x |
| Jun 2026 | 2.00x |
| Mar 2026 | 1.06x |
| Dec 2025 | 0.69x |
| Sep 2025 | 12.10x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.62x
TTM operating cash flow over long-term debt only, 2025-06-30 (12 months older than the period end)
Cash flow to debt LFMD
| FY Dec 2025 | 0.52x |
| FY Dec 2024 | 1.77x |
| FY Dec 2023 | 0.49x |
| FY Dec 2022 | -2.12x |
| FY Dec 2021 | -3.06x |
| Jun 2026 | -0.62x |
| Mar 2026 | 0.36x |
| Dec 2025 | 0.52x |
| Sep 2025 | 0.79x |
| Jun 2025 | 1.23x |
| Mar 2025 | 2.26x |
| Dec 2024 | 1.77x |
| Sep 2024 | 1.71x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-821.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LFMD
| FY Dec 2025 | -159.8% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -802.8% |
| FY Dec 2021 | -595.9% |
| Jun 2026 | -821.5% |
| Mar 2026 | -313.8% |
| Dec 2025 | -159.8% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-38.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LFMD
| FY Dec 2025 | -15.4% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +42.4% |
| FY Dec 2022 | -120.5% |
| FY Dec 2021 | -192.3% |
| Jun 2026 | -38.1% |
| Mar 2026 | -27.7% |
| Dec 2025 | -15.4% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +29.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital LFMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed LFMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -161.1% |
| FY Dec 2022 | -406.3% |
| FY Dec 2021 | -408.8% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -171.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing LFMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$79.9M
market value at close 2026-10-26 on 2026-08-04 shares, plus long-term debt only, 2025-06-30 (12 months older than the period end), minus cash 2025-06-30
Enterprise value LFMD
| FY Dec 2025 | $143.8M |
| FY Dec 2024 | $189.3M |
| FY Dec 2023 | $299.6M |
| FY Dec 2022 | $67.9M |
| FY Dec 2021 | $87.9M |
| Jun 2026 | $179.4M |
| Mar 2026 | $152.9M |
| Dec 2025 | $143.8M |
| Sep 2025 | $301.6M |
| Jun 2025 | $598.7M |
| Mar 2025 | $215.0M |
| Dec 2024 | $189.3M |
| Sep 2024 | $201.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-11.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield LFMD
| FY Dec 2025 | +3.9% |
| FY Dec 2024 | +7.5% |
| FY Dec 2023 | +2.7% |
| FY Dec 2022 | -38.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | -5.5% |
| Mar 2026 | +2.2% |
| Dec 2025 | +3.9% |
| Sep 2025 | +3.3% |
| Jun 2025 | +2.9% |
| Mar 2025 | +5.8% |
| Dec 2024 | +7.5% |
| Sep 2024 | +9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing LFMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $194.1M | $212.5M | $152.5M | $119.0M |
| Gross profit | $166.3M | $133.4M | $133.6M | $100.4M |
| Operating income | -$7.7M | -$20.4M | -$14.5M | -$43.4M |
| Net income | -$11.2M | $24.5M | $17.8M | -$45.5M |
| EPS (diluted) | 0.25 | -0.60 | n/a | n/a |
| Operating cash flow | $8.3M | $17.5M | $8.8M | -$22.9M |
| Cash | n/a | $35.0M | $33.1M | $4.0M |
| Long-term debt | n/a | $9.9M | $17.9M | n/a |
| Buybacks | $270.0K | n/a | n/a | n/a |
| Dividends paid | $3.1M | $3.1M | $3.1M | $3.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
LFMD Stock Sonar score 5/7 axes
Find similar shapesCompareLFMD ranks highest on growth (77th percentile) and risk and compliance (44th), and lowest on profitability (11th), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
